Skip to main content

X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · IEX Real-Time Price · USD
4.52
-0.16 (-3.42%)
At close: Nov 26, 2021 1:00 PM
4.46
-0.06 (-1.33%)
After-hours:Nov 26, 2021 1:05 PM EST
Market Cap111.68M
Revenue (ttm)n/a
Net Income (ttm)-85.13M
Shares Out24.71M
EPS (ttm)-3.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume466,655
Open4.99
Previous Close4.68
Day's Range4.47 - 4.66
52-Week Range4.20 - 10.70
Beta0.05
AnalystsStrong Buy
Price Target20.00 (+342.5%)
Earnings DateNov 4, 2021

About XFOR

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa c...

IndustryBiotechnology
Founded2014
Employees79
Stock ExchangeNASDAQ
Ticker SymbolXFOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 342.48% from the latest price.

Price Target
$20.00
(342.48% upside)
Analyst Consensus: Strong Buy

News

X4 Pharmaceuticals to Participate in Stifel's Virtual Healthcare Conference

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with di...

2 weeks ago - GlobeNewsWire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Sc...

Data continue to support mavorixafor's potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström's macroglobulinemia

3 weeks ago - GlobeNewsWire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with ...

3 weeks ago - GlobeNewsWire

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November ...

Earnings Call taking place at 9:05 a.m. ET expected to include discussion of abstracts accepted to the upcoming 63rd American Society of Hematology (ASH) Annual Meeting Earnings Call taking place at 9:0...

1 month ago - GlobeNewsWire

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Dire...

Each brings significant experience in strategic marketing of rare disease therapeutics and commercial operations Each brings significant experience in strategic marketing of rare disease therapeutics an...

1 month ago - GlobeNewsWire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

1 month ago - GlobeNewsWire

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dy...

2 months ago - GlobeNewsWire

X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dy...

2 months ago - GlobeNewsWire

X4 Pharmaceuticals to Participate at Canaccord Genuity's Virtual 41st Annual Growth Conference

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dys...

3 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports...

Twenty-three patients now enrolled in ongoing pivotal Phase 3 trial in WHIM syndrome, surpassing minimum needed for primary endpoint analyses; enrollment to complete in 3Q21 with top-line data expected ...

3 months ago - GlobeNewsWire

X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August...

BOSTON, July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

4 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Wal...

Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström's patients; meaningful increases in hemoglobin l...

5 months ago - GlobeNewsWire

X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Post...

Poster presentation by lead author Dr. Steven Treon available on the EHA website  Friday, June 11, 2021 at 9:00 am CET/3:00 am ET

6 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldens...

Initial data from first cohort of patients indicate mavorixafor plus ibrutinib to be well tolerated, with encouraging decreases in serum IgM observed

6 months ago - GlobeNewsWire

X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

Company continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications

6 months ago - GlobeNewsWire

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, ...

BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR...

7 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR...

7 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing

BOSTON, March 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR...

8 months ago - GlobeNewsWire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

2021 expected to be a year of key value-driving catalysts as company advances multiple  clinical programs with lead candidate mavorixafor

8 months ago - GlobeNewsWire

X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference

BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

10 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

10 months ago - GlobeNewsWire

X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher

X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

11 months ago - GlobeNewsWire

X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syn...

BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

11 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

11 months ago - GlobeNewsWire